cagrilintide/semaglutide vs pramlintide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Amylin receptor · full Type 2 Diabetes pipeline

cagrilintide/semaglutide · CagriSema

Developed by Novo Nordisk

Phase 3 in Type 2 Diabetespeptide
Reliable signal

NCT05394519 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.

Next expected readout: June 2027 · NCT07817251 (registry estimate)

Reported efficacy

Relative change in body weight (From baseline (week 0) to end of treatment (week 68)); Achievement of greater than or equal to (≥) 5% weight reduction (From baseline (week 0) to end of treatment (week 68)): Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) (met)

Result source: NCT05394519

pramlintide · Symlin

Rights held by AstraZeneca; US product discontinued

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcagrilintide/​semaglutidepramlintide
HbA1c, change—Not posted · NCT05394519—Not posted · NCT00108004
Body weight, change (kg)—Not posted · NCT05394519—Not posted · NCT00108004
HbA1c below 7%—Not posted · NCT05394519—Not posted · NCT00108004
Fasting plasma glucose, change—Not posted · NCT05394519—Not posted · NCT00108004
3-point MACE (% with event)—Not posted · NCT05394519—Not posted · NCT00108004

HbA1c, change

cagrilintide/​semaglutide
—Not posted · NCT05394519
pramlintide
—Not posted · NCT00108004

Body weight, change (kg)

cagrilintide/​semaglutide
—Not posted · NCT05394519
pramlintide
—Not posted · NCT00108004

HbA1c below 7%

cagrilintide/​semaglutide
—Not posted · NCT05394519
pramlintide
—Not posted · NCT00108004

Fasting plasma glucose, change

cagrilintide/​semaglutide
—Not posted · NCT05394519
pramlintide
—Not posted · NCT00108004

3-point MACE (% with event)

cagrilintide/​semaglutide
—Not posted · NCT05394519
pramlintide
—Not posted · NCT00108004
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

pramlintide: registry results are on file for Type 2 Diabetes, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

cagrilintide/semaglutide

Weight -13.7% vs -3.4% placebo @ 68wk
percent change · % of baseline
NCT05394519 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide/semaglutide's landscape · pramlintide's landscape